BioSpace News Archive

KemPharm, Inc. today announced that Richard W. Pascoe, Chief Executive Officer of KemPharm, has issued a Letter to Shareholders.

BioVentrix ® , Inc. today announced the US Food and Drug Administration (FDA) has approved its application for an Expanded Access Program (EAP) for Revivent TC® System.

Cerevance announced that Craig Thompson, chief executive officer of Cerevance, will participate in the upcoming SVB Global Biopharma Conference.

Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personalized lifestyle and weight reduction programs, announces initial results from patient studies of its metabolic health program Miboko with the National Health Service (NHS) in the United Kingdom.

Avadel Pharmaceuticals plc today announced the publication of real-world data describing the risk of accidental dosing errors with immediate-release twice-nightly oxybate.

Baudax Bio, Inc. today announced the successful outcome of its first interim analysis in a Phase II trial of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery.

Geneoscopy Inc. , a life sciences company focused on the development of diagnostic tests for gastrointestinal health, announced today it submitted a Premarket Approval (PMA) application to the U.S. Food and Drug Administration.

Incyte (Nasdaq:INCY) announced today that it will present at the Guggenheim Healthcare Talks l Oncology Day on Wednesday, February 8, 2023 at 1:35 p.m. (EST) in New York.

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, announced its latest collaboration with Transcoject GmbH, a medical device and pharma packaging solutions company.

Diamond Therapeutics Inc. is pleased to announce it has received Health Canada approval to begin a Phase 2 clinical trial evaluating the safety, tolerability and efficacy of repeat low-doses of psilocybin for the treatment of generalized anxiety disorder (GAD).